San Diego-based genomics equipment maker Illumina announced Tuesday its acquisition of Conexio Genomics, a 14-year-old Australian firm that specializes in typing used to match patients and donors for bone marrow or cord blood transplants.
Conexio’s system uses a protein found in most cells in the body — human leukocyte antigen or HLA.
“The addition of Conexio products and people solidify our HLA capabilities and demonstrate Illumina’s ongoing commitment to HLA and ultimately, to the field of transplant science,” said Alex Lindell, associate director of HLA market development at Illumina.
Illumina and Conexio began a partnership about one year ago to develop the TruSight HLA Sequencing Panel, an HLA typing kit.
Conexio’s next-generation sequencing development programs will be immediately integrated into Illumina, company officials said.
—City News Service
